CA2834713A1 - Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters - Google Patents

Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters Download PDF

Info

Publication number
CA2834713A1
CA2834713A1 CA2834713A CA2834713A CA2834713A1 CA 2834713 A1 CA2834713 A1 CA 2834713A1 CA 2834713 A CA2834713 A CA 2834713A CA 2834713 A CA2834713 A CA 2834713A CA 2834713 A1 CA2834713 A1 CA 2834713A1
Authority
CA
Canada
Prior art keywords
azabicyclo
hexane
dichlorophenyl
agent
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2834713A
Other languages
English (en)
French (fr)
Inventor
Anthony Alexander Mckinney
Frank Bymaster
Walter Piskorski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euthymics Bioscience Inc
Original Assignee
Euthymics Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euthymics Bioscience Inc filed Critical Euthymics Bioscience Inc
Publication of CA2834713A1 publication Critical patent/CA2834713A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2834713A 2010-12-03 2011-12-02 Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters Abandoned CA2834713A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41976910P 2010-12-03 2010-12-03
US61/419,769 2010-12-03
PCT/US2011/063193 WO2012075473A1 (en) 2010-12-03 2011-12-02 Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters

Publications (1)

Publication Number Publication Date
CA2834713A1 true CA2834713A1 (en) 2012-06-07

Family

ID=46172308

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2834713A Abandoned CA2834713A1 (en) 2010-12-03 2011-12-02 Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters

Country Status (8)

Country Link
US (5) US20120258994A1 (https=)
EP (1) EP2646019A4 (https=)
JP (3) JP2013544850A (https=)
KR (1) KR20140053822A (https=)
AU (1) AU2011336318A1 (https=)
BR (1) BR112013013572A2 (https=)
CA (1) CA2834713A1 (https=)
WO (1) WO2012075473A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
KR20110071064A (ko) 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) * 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US20150366501A1 (en) * 2013-01-28 2015-12-24 Brc Operations Pty Limited White matter diffusion tensor imaging test to predict treatment outcomes in medical treatment
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014134569A1 (en) * 2013-02-28 2014-09-04 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
JP2016518406A (ja) * 2013-05-07 2016-06-23 ユーシミクス・バイオサイエンス・インコーポレイテッドＥｕｔｈｙｍｉｃｓ Ｂｉｏｓｃｉｅｎｃｅ，Ｉｎｃ． 嗜癖障害およびアルコール関連障害を治療するための（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］へキサンの使用
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2930410A1 (en) * 2013-11-11 2015-05-14 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
CN104683094B (zh) * 2013-11-29 2018-10-26 上海华虹集成电路有限责任公司 用于rsa密码的蒙哥马利阶梯算法
KR20160101012A (ko) 2013-12-09 2016-08-24 뉴로반스, 인크. 신규 조성물
DK3474844T3 (da) 2016-06-28 2022-08-29 Trichomeshell Ltd Doseringsform til fordampning og rygning
EP3797818B1 (en) * 2018-05-23 2023-01-18 Shanghai WD Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020142545A1 (en) 2018-12-31 2020-07-09 Ethismos Research, Inc. Novel methods
US11554154B2 (en) * 2020-07-22 2023-01-17 Biolite, Inc. Polygala extract for the treatment of major depressive disorder
CA3230068A1 (en) * 2021-08-31 2023-03-09 Ethismos Research, Inc. Methods of preventing and treating pain and associated symptoms
CN116813547A (zh) * 2023-06-29 2023-09-29 爱斯特（成都）生物制药股份有限公司 一种制备3-氮杂双环[3，2，1]辛烷盐酸盐的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
MX2007001827A (es) * 2004-08-18 2007-04-23 Dov Pharmaceutical Inc Nuevas sustancias polimorfas de azabiciclohexano.
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
US20140228421A1 (en) * 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders

Also Published As

Publication number Publication date
JP2019031502A (ja) 2019-02-28
US20210161863A1 (en) 2021-06-03
US20190358199A1 (en) 2019-11-28
EP2646019A1 (en) 2013-10-09
US20180256542A1 (en) 2018-09-13
EP2646019A4 (en) 2014-05-21
WO2012075473A1 (en) 2012-06-07
US20120258994A1 (en) 2012-10-11
BR112013013572A2 (pt) 2016-10-11
KR20140053822A (ko) 2014-05-08
JP2013544850A (ja) 2013-12-19
JP2017114861A (ja) 2017-06-29
US20140039029A1 (en) 2014-02-06
AU2011336318A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
US20210161863A1 (en) Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US20240409514A1 (en) Methods for inhibiting native and promiscuous uptake of monoamine neurotransmitters
US11939312B2 (en) Enantiomeric entactogen compositions and their use
US12042481B2 (en) Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US12459912B2 (en) Advantageous benzothiophene compositions for mental disorders or enhancement
AU686706B2 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
EP2819516B1 (en) Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters
JP7096813B2 (ja) 組成物及びその方法
KR20230066313A (ko) 정신 장애 또는 정신적 증강에 유리한 벤조푸란 조성물
US20120258172A1 (en) Compositions For The Treatment of Central Nervous System Disorders Including Depression Employing Novel Drug Combination Therapy To Reduce Suicidality In Patients
CN1496349A (zh) (+)-1-(3,4-二氯苯基)-3-氮杂二环[3.1.0]己烷及其组合物与应用
WO2012074561A2 (en) Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
US20160346249A1 (en) Use of amitifadine, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in methods and compositions with enhanced efficacy and reduced metabolic side effects and toxicity for treatment of depression and other central nervous system disorders and conditions affected by monoamine neurotransmitters
US20020193380A1 (en) Method for treatment of pain
Center et al. 2) Patent Application Publication o Pub. No.: US 2021/0161863 A1
AU2017276293A1 (en) Opsin-binding ligands, compositions and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161202

FZDE Discontinued

Effective date: 20181204